Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice

被引：175

作者：

Huisman, Menno V. ^{[1
,2
]}

Lip, Gregory Y. H. ^{[3
]}

Diener, Hans-Christoph ^{[4
]}

Brueckmann, Martina ^{[5
]}

van Ryn, Joanne ^{[6
]}

Clemens, Andreas ^{[5
]}

机构：

[1] Leiden Univ, Dept Thrombosis, Med Ctr, Leiden, Netherlands

[2] Leiden Univ, Dept Haemostasis, Med Ctr, Leiden, Netherlands

[3] Univ Birmingham, Ctr Cardiovasc Sci, City Hosp, Birmingham, W Midlands, England

[4] Univ Hosp Essen, Dept Neurol, Essen, Germany

[5] Boehringer Ingelheim GmbH & Co KG, Global Clin Dev & Med Affairs, Ingelheim, Germany

[6] Boehringer Ingelheim Pharma GmbH & Co KG, Dept CardioMetab Dis Res, Biberach An Der Riss, Germany

来源：

THROMBOSIS AND HAEMOSTASIS | 2012年 / 107卷 / 05期

关键词：

Dabigatran; atrial fibrillation; oral anticoagulant; bleeding; DIRECT THROMBIN INHIBITOR; ANTITHROMBOTIC THERAPY; CONSENSUS DOCUMENT; ISCHEMIC-STROKE; EUROPEAN-SOCIETY; OPEN-LABEL; WARFARIN; RISK; ANTICOAGULATION; GUIDELINES;

D O I：

10.1160/TH11-10-0718

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Dabigatran etexilate is a new oral anticoagulant recently approved in Europe for the prevention of stroke or systemic embolism in adult patients with non-valvular atrial fibrillation (AF) and at least one risk factor for stroke. With a fast onset of action and a predictable anticoagulant effect obviating the need for coagulation monitoring, dabigatran etexilate offers practical advantages over vitamin K antagonists in clinical practice. However, clinicians may have questions about practical aspects of dabigatran etexilate use including monitoring anticoagulant efficacy, interruption for surgical or invasive procedures and management of bleeding. This review article aims to address these concerns and provide guidance on the use of dabigatran etexilate in special situations, such as acute coronary syndromes and cardiac revascularisation. In addition, cut-off values for different coagulation assay results associated with an increased risk of bleeding are given.

引用

页码：838 / 847

页数：10

共 58 条

[1] Guidelines for the early management of adults with ischemic stroke -: A guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups (Reprinted from Stroke, vol 38, pg 1655-1711, 2007) [J].

Adams, Harold P., Jr. ;

del Zoppo, Gregory ;

Alberts, Mark J. ;

Bhatt, Deepak L. ;

Brass, Lawrence ;

Furlan, Anthony ;

Grubb, Robert L. ;

Higashida, Randall T. ;

Jauch, Edward C. ;

Kidwell, Chelsea ;

Lyden, Patrick D. ;

Morgenstern, Lewis B. ;

Qureshi, Adnan I. ;

Rosenwasser, Robert H. ;

Scott, Phillip A. ;

Wijdicks, Eelco F. M. .

CIRCULATION, 2007, 115 (20) :E478-E534

[2] New oral anticoagulant drugs in cardiovascular disease [J].

Ahrens, Ingo ;

Lip, Gregory Y. H. ;

Peter, Karlheinz .

THROMBOSIS AND HAEMOSTASIS, 2010, 104 (01) :49-60

[3]

[Anonymous], PRAD SUMM PROD CHAR

[4]

[Anonymous], RE ALIGN RAND PHAS 2

[5]

[Anonymous], 2011, COMM MED PROD HUM US

[6]

Baruch Lawrence, 2011, Ann Pharmacother, V45, pe40, DOI 10.1345/aph.1Q105

[7] Consensus document on antithrombotic therapy in the setting of electrophysiological procedures [J].

Blanc, Jean Jacques ;

Almendral, Jesus ;

Brignole, Michele ;

Fatemi, Marjaneh ;

Gjesdal, Knut ;

Gonzalez-Torrecilla, Esteban ;

Kulakowski, Piotr ;

Lip, Gregory Y. H. ;

Shah, Dipen ;

Wolpert, Christian .

EUROPACE, 2008, 10 (05) :513-527

[8] The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans [J].

Blech, Stefan ;

Ebner, Thomas ;

Ludwig-Schwellinger, Eva ;

Stangier, Joachim ;

Roth, Willy .

DRUG METABOLISM AND DISPOSITION, 2008, 36 (02) :386-399

[9]

Boehringer Ingelheim, ADV COMM BRIEF DOC

[10]

Brunet A, 2011, EUR HEART J, V32, P618

← 1 2 3 4 5 6 →